[go: up one dir, main page]

PE20212078A1 - Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis - Google Patents

Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis

Info

Publication number
PE20212078A1
PE20212078A1 PE2020000568A PE2020000568A PE20212078A1 PE 20212078 A1 PE20212078 A1 PE 20212078A1 PE 2020000568 A PE2020000568 A PE 2020000568A PE 2020000568 A PE2020000568 A PE 2020000568A PE 20212078 A1 PE20212078 A1 PE 20212078A1
Authority
PE
Peru
Prior art keywords
treatment
compound
osteoarthritis pain
mpges
inhibitor
Prior art date
Application number
PE2020000568A
Other languages
English (en)
Inventor
Monika Tandon
Sumit Sant
Neelima Khairatkar-Joshi
Girish Gudi
Vinu C A Menon
Ravi Talluri
Original Assignee
Ichnos Sciences S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences S A filed Critical Ichnos Sciences S A
Publication of PE20212078A1 publication Critical patent/PE20212078A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido al compuesto N-(4-cloro-3-(5-oxo-1-(4-(trifluorometil)fenil)-4,5-dihidro-1H-1,2,4-triazol-3-5 il)bencil)pivalamida (Compuesto I), o una sal farmaceuticamente aceptable de este, en donde el compuesto I es un inhibidor de la prostaglandina E sintasa microsomal 1 (mPGES-1), siendo util para el tratamiento del dolor por osteoartritis. Tambien se refiere a composiciones farmaceuticas, administracion de dicho compuesto y su uso en el tratamiento.
PE2020000568A 2017-09-20 2018-09-20 Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis PE20212078A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721033369 2017-09-20
IN201721042452 2017-11-27
PCT/IB2018/057244 WO2019058295A1 (en) 2017-09-20 2018-09-20 INHIBITOR OF MPGES-1 FOR THE TREATMENT OF ARTHROSIS PAIN

Publications (1)

Publication Number Publication Date
PE20212078A1 true PE20212078A1 (es) 2021-10-28

Family

ID=63794565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000568A PE20212078A1 (es) 2017-09-20 2018-09-20 Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis

Country Status (15)

Country Link
US (1) US10758517B2 (es)
EP (1) EP3684356A1 (es)
JP (1) JP2020534310A (es)
KR (1) KR20200094132A (es)
CN (1) CN111526875A (es)
AU (1) AU2018338045A1 (es)
BR (1) BR112020005573A2 (es)
CA (1) CA3076480A1 (es)
CO (1) CO2020004599A2 (es)
IL (1) IL273364A (es)
MX (1) MX2020003045A (es)
PE (1) PE20212078A1 (es)
PH (1) PH12020500393A1 (es)
SG (1) SG11202002307TA (es)
WO (1) WO2019058295A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654956A1 (en) * 2023-01-26 2025-12-03 Insignia Pharmaceuticals, LLC Pharmaceutical compositions for treating osteoarthritis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
TR201906040T4 (tr) 2014-08-01 2019-05-21 Glenmark Pharmaceuticals Sa Bir mPGES-1 inhibitörü içeren nanopartikülat formülasyon.

Also Published As

Publication number Publication date
KR20200094132A (ko) 2020-08-06
CO2020004599A2 (es) 2020-07-31
MX2020003045A (es) 2020-09-14
CA3076480A1 (en) 2019-03-28
EP3684356A1 (en) 2020-07-29
IL273364A (en) 2020-05-31
CN111526875A (zh) 2020-08-11
WO2019058295A1 (en) 2019-03-28
US20190175562A1 (en) 2019-06-13
AU2018338045A1 (en) 2020-04-02
BR112020005573A2 (pt) 2020-10-27
SG11202002307TA (en) 2020-04-29
US10758517B2 (en) 2020-09-01
PH12020500393A1 (en) 2021-01-04
JP2020534310A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
PE20220766A1 (es) Agonistas de receptor de melanocortina-4
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CR20220371A (es) Agonistas heterocíclicos de glp-1
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA202091893A1 (ru) Новые кристаллические формы
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
EA202191286A1 (ru) Ингибитор 15-pgdh
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
PE20200924A1 (es) Compuestos de bisamida sustituida que activan el sarcomero cardiaco
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
PE20180575A1 (es) Benzamidas sustituidas y metodos para utilizarlas
EA202192320A1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида
PE20212323A1 (es) Formulaciones farmaceuticas
JOP20220093A1 (ar) تركيبة صيدلانية تشتمل على سيليكسيباغ
JOP20190050A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
EA202191833A1 (ru) Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида